The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands
Open accessAbstract
UNLABELLED: 11C-PBR28 PET can detect the 18-kDa translocator protein (TSPO) expressed within macrophages. However, quantitative evaluation of the signal in brain tissue from donors with multiple sclerosis (MS) shows that PBR28 binds the TSPO with high affinity (binding affinity [Ki], ∼4 nM), low affinity (Ki, ∼200 nM), or mixed affinity (2 sites with Ki, ∼4 nM and ∼300 nM). Our study tested whether similar binding behavior could be detected in brain tissue from donors with no history of neurologic disease, with TSPO-binding PET ligands other than 11C-PBR28, for TSPO present in peripheral blood, and with human brain PET data acquired in vivo with 11C-PBR28. METHODS: The affinity of TSPO ligands was measured in the human brain postmortem from donors with a history of MS (n=13), donors without any history of neurologic disease (n=20), and in platelets from healthy volunteers (n=13). Binding potential estimates from thirty-five 11C-PBR28 PET scans from an independent sample of healthy volunteers were analyzed using a gaussian mixture model. RESULTS: Three binding affinity patterns were found in brains from subjects without neurologic disease in similar proportions to those reported previously from studies of MS brains. TSPO ligands showed substantial differences in affinity between subjects classified as high-affinity binders (HABs) and low-affinity binders (LABs). Differences in affinity between HABs and LABs are approximately 50-fold with PBR28, approximately 17-fold with PBR06, and approximately 4-fold with DAA1106, DPA713, and PBR111. Where differences in affinity between HABs and LABs were low (∼4-fold), distinct affinities were not resolvable in binding curves for mixed-affinity binders (MABs), which appeared to express 1 class of sites with an affinity approximately equal to the mean of those for HABs and LABs. Mixed-affinity binding was detected in platelets from an independent sample (HAB, 69%; MAB, 31%), although LABs were not detected. Analysis of 11C-PBR28 PET data was not inconsistent with the existence of distinct subpopulations of HABs, MABs, and LABs. CONCLUSION: With the exception of 11C-PK11195, all TSPO PET ligands in current clinical application recognize HABs, LABs, and MABs in brain tissue in vitro. Knowledge of subjects' binding patterns will be required to accurately quantify TSPO expression in vivo using PET.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Self-citationComparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas
Floeth, F. W., Sabel, M., Ewelt, C., Stummer, W., Felsberg, J., Reifenberger, G., Steiger, H. J., Stoffels, G., Coenen, H. H., & Langen, K.-J. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1690-z · Cited by 281
Kreisl, W. C., Fujita, M., Fujimura, Y., Kimura, N., Jenko, K. J., Kannan, P., Hong, J., Morse, C. L., Zoghbi, S. S., Gladding, R. L., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.056 · Cited by 274
Self-citationYasuno, F., Ota, M., Kosaka, J., Ito, H., Higuchi, M., Doronbekov, T. K., Nozaki, S., Fujimura, Y., Koeda, M., Asada, T., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.021 · Cited by 221
Fujita, M., Imaizumi, M., Zoghbi, S. S., Fujimura, Y., Farris, A. G., Suhara, T., Hong, J., Pike, V. W., & Innis, R. B. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.11.011 · Cited by 213
Self-citationOwen, D. R., Howell, O. W., Tang, S.-P., Wells, L. A., Bennacef, I., Bergstrom, M., Gunn, R. N., Rabiner, E. A., Wilkins, M. R., Reynolds, R., et al. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.63 · Cited by 210
Self-citationOkubo, T., Yoshikawa, R., Chaki, S., Okuyama, S., & Nakazato, A. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.10.050 · Cited by 158
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 893
Owen, D. R., Yeo, A. J., Gunn, R. N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D. J., Bennacef, I., Parker, C. A., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.147 · Cited by 779
Self-citationHamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., et al. (2016) · Brain · doi:10.1093/brain/aww017 · Cited by 519
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
“In addition, a very recent tracer named [18F]-FEPPA is able to provide a high potential for TSPO-PET in humans (192).”
BackgroundBeumer, W., Gibney, S. M., Drexhage, R. C., Pont-Lezica, L., Doorduin, J., Klein, H. C., Steiner, J., Connor, T. J., Harkin, A., Versnel, M. A., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0212100 · Cited by 347
“ties for the polymorphisms of the TSPO in humans, resulting in low-, mixed-, and high-affinity binding [78, 79].”
BackgroundIn vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease
Kreisl, W. C., Lyoo, C. H., McGwier, M., Snow, J., Jenko, K. J., Kimura, N., Corona, W., Morse, C. L., Zoghbi, S. S., Pike, V. W., et al. (2013) · Brain · doi:10.1093/brain/awt145 · Cited by 350
“The main limitation of 11 C-PBR28, shared by all tested second generation TSPO radioligands (including 11 C-DAA1106), is differential affinity for the target protein (Owen et al ., 2011).”
BackgroundSelf-citationPositron emission tomography molecular imaging for drug development
Matthews, P. M., Rabiner, E. A., Passchier, J., & Gunn, R. N. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04085.x · Cited by 320
Self-citationNeuroinflammation in Neurodegenerative Disorders-a Review
Schain, M., & Kreisl, W. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0733-2 · Cited by 301
Self-citationWerry, E. L., Bright, F. M., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kril, J. J., & Kassiou, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133161 · Cited by 279
Structure of the Mitochondrial Translocator Protein in Complex with a Diagnostic Ligand
Jaremko, Ł., Jaremko, M., Giller, K., Becker, S., & Zweckstetter, M. (2014) · Science · doi:10.1126/science.1248725 · Cited by 259
Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis
Corcia, P., Tauber, C., Vercoullie, J., Arlicot, N., Prunier, C., Praline, J., Nicolas, G., Venel, Y., Hommet, C., Baulieu, J.-L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052941 · Cited by 249
Noninvasive Molecular Imaging of Neuroinflammation
Jacobs, A. H., Tavitian, B., & the INMiND consortium (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.53 · Cited by 245
Hamelin, L., Lagarde, J., Dorothée, G., Potier, M. C., Corlier, F., Kuhnast, B., Caillé, F., Dubois, B., Fillon, L., Chupin, M., et al. (2018) · Brain · doi:10.1093/brain/awy079 · Cited by 177
Kraynak, T. E., Marsland, A. L., Wager, T. D., & Gianaros, P. J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.013 · Cited by 165
Mizrahi, R., Rusjan, P. M., Kennedy, J., Pollock, B., Mulsant, B., Suridjan, I., De Luca, V., Wilson, A. A., & Houle, S. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.46 · Cited by 155
Yasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., Nozaki, S., Takahashi, S., Mizukami, K., Asada, T., et al. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.08.013 · Cited by 148
Suridjan, I., Pollock, B. G., Verhoeff, N. P. L. G., Voineskos, A. N., Chow, T., Rusjan, P. M., Lobaugh, N. J., Houle, S., Mulsant, B. H., & Mizrahi, R. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.1 · Cited by 132
Rizzo, G., Veronese, M., Tonietto, M., Zanotti-Fregonara, P., Turkheimer, F. E., & Bertoldo, A. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.55 · Cited by 121
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121
“binding class determined on the basis of the number of high- versus low-affinity sites [81,82].”
BackgroundResultMicroglial activation in Parkinson’s disease using [18F]-FEPPA
Ghadery, C., Koshimori, Y., Coakeley, S., Harris, M., Rusjan, P., Kim, J., Houle, S., & Strafella, A. P. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0778-1 · Cited by 113
“Nonetheless, since the genetic variability is present in healthy as well as in diseaseaffected brains, it cannot be associated with a specific neurological condition [12, 36].”
Sifting through the surfeit of neuroinflammation tracers
Cumming, P., Burgher, B., Patkar, O., Breakspear, M., Vasdev, N., Thomas, P., Liu, G.-J., & Banati, R. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17748786 · Cited by 111
Mapping microglia and astrocyte activation in vivo using diffusion MRI
Garcia-Hernandez, R., Cerdán Cerdá, A., Trouve Carpena, A., Drakesmith, M., Koller, K., Jones, D. K., Canals, S., & De Santis, S. (2022) · Science Advances · doi:10.1126/sciadv.abq2923 · Cited by 102
Watkins, C. C., Sawa, A., & Pomper, M. G. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.119 · Cited by 100
In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Garibotto, V., & Millet, P. (2020) · Cells · doi:10.3390/cells9091941 · Cited by 79
Cerami, C., Iaccarino, L., & Perani, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050993 · Cited by 75
Suridjan, I., Rusjan, P. M., Voineskos, A. N., Selvanathan, T., Setiawan, E., Strafella, A. P., Wilson, A. A., Meyer, J. H., Houle, S., & Mizrahi, R. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.09.021 · Cited by 71
Astrocytic TSPO upregulation appears before microglial TSPO in Alzheimer’s disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Fraser, B. H., Grégoire, M.-C., Kövari, E., & Millet, P. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200136 · Cited by 65
Ricigliano, V. A. G., Louapre, C., Poirion, E., Colombi, A., Yazdan Panah, A., Lazzarotto, A., Morena, E., Martin, E., Bottlaender, M., Bodini, B., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200026 · Cited by 64
Wang, Q., Wang, Y., Liu, J., Sutphen, C. L., Cruchaga, C., Blazey, T., Gordon, B. A., Su, Y., Chen, C., Shimony, J. S., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101767 · Cited by 63
Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging
Zhang, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0236-5 · Cited by 62
Tournier, B. B., Tsartsalis, S., Rigaud, D., Fossey, C., Cailly, T., Fabis, F., Pham, T., Grégoire, M.-C., Kövari, E., Moulin-Sallanon, M., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.022 · Cited by 62
Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer’s disease
Faculty, O. B. O. T. M., Boche, D., Gerhard, A., & Rodriguez-Vieitez, E. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04462-w · Cited by 55
Finze, A., Biechele, G., Rauchmann, B.-S., Franzmeier, N., Palleis, C., Katzdobler, S., Weidinger, E., Guersel, S., Schuster, S., Harris, S., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02188-8 · Cited by 40
Translocator protein 18 kDa (TSPO) expression in multiple sclerosis patients
Harberts, E., Datta, D., Chen, S., Wohler, J. E., Oh, U., & Jacobson, S. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9397-5 · Cited by 36
(2022) · doi:10.1101/2022.11.12.22282082 · Cited by 4
Metadata
- Authors
- Owen, D. R. J., Gunn, R. N., Rabiner, E. A., Bennacef, I., Fujita, M., Kreisl, W. C., Innis, R. B., Pike, V. W., Reynolds, R., Matthews, P. M., & Parker, C. A.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2010-12-13
- Volume
- 52
- Issue
- 1
- Pages
- 24-32
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2154119533
- Cited by
- 358
- References
- 14
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.